is double autologous transplantation in multiple myeloma superior in the age of new agents?
Published 7 years ago • 129 plays • Length 3:44Download video MP4
Download video MP3
Similar videos
-
1:57
the benefit of double autologous transplantation in multiple myeloma patient subgroups
-
2:22
the benefit of autologous transplantation in the era of novel agents in multiple myeloma
-
1:27
the use of salvage second autologous transplant in the age of novel therapies for multiple myeloma
-
2:10
phase ii study of epd maintenance after second autologous transplant for multiple myeloma
-
2:39
the role of tandem transplantation in multiple myeloma & how this may be impacted by novel agents
-
2:28
is autologous stem cell transplantation still the backbone of multiple myeloma treatment?
-
1:43
feasibility of double autologous stem cell transplantation in patients with al amyloidosis
-
6:23
how long will i live with multiple myeloma and is there a cure?
-
5:59
what is hrmm (high-risk multiple myeloma)?
-
2:49
the importance of timing in autologous transplantation for multiple myeloma
-
1:00
the role of non-covalent btk inhibitors in the treatment of non-hodgkin lymphoma
-
1:22
the potential use of car-t therapy following autologous transplantation in multiple myeloma
-
1:52
upfront asct for newly diagnosed multiple myeloma: double vs. single transplant
-
2:48
can car-t therapy be used in conjunction with or instead of autologous transplantation in myeloma?
-
2:39
a look into the future of multiple myeloma treatment: t-cell redirecting therapies vs autohsct
-
1:33
the role of allogeneic transplantation in patients with multiple myeloma
-
1:59
the role of upfront double auto-sct in high-risk myeloma
-
2:30
a new era of treatment for multiple myeloma
-
1:30
risk assessment & transplant decisions in multiple myeloma
-
1:04
the changing role of autosct in the treatment of multiple myeloma in the era of novel agents
-
1:30
exploring the role of upfront autosct in multiple myeloma